|
01 Apr 2019 |
Bolt Biotherapeutics Presents Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference
|
|
01 Apr 2019 |
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
|
|
01 Apr 2019 |
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
|
|
01 Apr 2019 |
BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients
|
|
01 Apr 2019 |
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
|
|
01 Apr 2019 |
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
|
|
01 Apr 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
|
|
01 Apr 2019 |
European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
|
|
01 Apr 2019 |
Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH
|
|
01 Apr 2019 |
Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application
|
|
01 Apr 2019 |
Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
|
|
01 Apr 2019 |
Oncorus Presents Preclinical Data Supporting the Advancement of its Lead Oncolytic Virus Therapy Clinical Candidate, ONCR-177
|
|
01 Apr 2019 |
PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
|
|
01 Apr 2019 |
Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium
|
|
01 Apr 2019 |
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
|
|
01 Apr 2019 |
ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer
|
|
01 Apr 2019 |
BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140
|
|
01 Apr 2019 |
Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor
|
|
01 Apr 2019 |
Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
|
|
31 Mar 2019 |
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
|
